In a statement to the press today, ImClone Chairman Carl Icahn said that the review committee overlooking Bristol-Myers Squibb’s offer to purchase the biotech company for $60 per share $4.5 billion just isn’t good enough.
He not only accused BMS of lowballing, but also admitted that the company has been in talks with the head of [...]

[Read more →]